诺和诺德的减肥药Wegovy近日获美国FDA批准新用途，可用于治疗代谢功能障碍相关脂肪性肝炎（MASH），消息推动公司股价盘前上涨。这一突破使诺和诺德在激烈的GLP-1药物市场竞争中，针对MASH领域抢占先发优势，以扭转年初以来的市值颓势。诺和诺德的重磅药物Wegovy在一场关键竞争中胜出，股价随之上涨。据媒体18日报道，美国食品药品监督管理局（FDA）于上周五晚间批准了Wegovy用于新适应症的...
Source Link诺和诺德的减肥药Wegovy近日获美国FDA批准新用途，可用于治疗代谢功能障碍相关脂肪性肝炎（MASH），消息推动公司股价盘前上涨。这一突破使诺和诺德在激烈的GLP-1药物市场竞争中，针对MASH领域抢占先发优势，以扭转年初以来的市值颓势。诺和诺德的重磅药物Wegovy在一场关键竞争中胜出，股价随之上涨。据媒体18日报道，美国食品药品监督管理局（FDA）于上周五晚间批准了Wegovy用于新适应症的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.